BioClinica Partners with Mirada Medical for New Era of Molecular Image Analysis

– Announces Record Backlog of $125.8 million –

– Mirada XD3 Analysis Software to Integrate with BioREAD Imaging Core Lab System for PET and Molecular Imaging in Oncology and Other Therapeutic Areas –

March 30, 2012.  NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced a partnership with Mirada Medical, a leading provider of medical image analysis software. BioClinica will integrate Mirada's XD3 software solution into its imaging core lab technology to further enhance its PET capabilities and expertise for molecular imaging trials.

Mirada Medical's software provides unique tools and efficient workflows for the quantification and tracking of findings for major modalities including PET, CT, MR and MR/PET. After a careful evaluation of available molecular imaging solutions, BioClinica selected Mirada for its advanced image analysis capabilities and ability to handle not only PET images but CT and MRI as well. This will further enhance BioClinica's image registration and fusion capabilities in studies where multiple modalities are utilized.

BioClinica's strategy goes beyond a standard utilization of Mirada's software by creating a strategic partnership that will foster innovation as the molecular imaging field continues to develop. BioClinica will integrate Mirada's XD3 image analysis software platform into its processes and workflows, adopting an innovative design that will advance the clinical capabilities of BioClinica technologies such as BioPACS and BioREAD. These high-performing imaging workflow and processing programs will now have expanded capabilities to help trial sponsors harness the superior imaging results that are achievable through PET scans and multi-modal technology.

Through this partnership, BioClinica's PET image processing capabilities will extend oncology clinical trials with support for the following features:

  • Enhanced capabilities for PERCIST tumor response assessment criteria
  • Normalization of uptake by body weight, lean body mass, or body surface area for SUV measurements
  • Registration and fusion capabilities between PET, CT, and MR
  • Customizable workflow and user interface to provide flexibility in the independent read design

"Adding Mirada technology to our oncology trial process takes BioClinica's already robust imaging core lab services to a new level," said Dr. Andy Dzik-Jurasz, BioClinica's Senior Medical Director of Medical Affairs. "By adding XD3 to our workflow, BioClinica will offer the most sophisticated level of clinical analysis available for oncology PET scan image processing."

"Mirada is delighted to partner with an innovative industry leader like BioClinica," said Timor Kadir, Chief Science and Technology Officer at Mirada Medical. "We are excited to see BioClinica's innovative utilization of XD3's superior quantification and world class image fusion to achieve more accurate and reproducible results for their trial sponsors."

As part of this partnership, Mirada Medical will present at BioClinica's upcoming User Conference in October. The BioClinica User Conference consists of two days of valuable presentations, case studies and discussions designed to help BioClinica imaging core lab customers and eClinical solution users discover new ways to run faster, more efficient clinical trials. To learn more about the conference, visit http://www.bioclinica.com/User-Conference-2012.

About Mirada Medical Ltd
Mirada Medical is a leading international brand in medical imaging. The company develops advanced software applications which help healthcare professionals use medical images more effectively and efficiently to improve cancer care. Mirada's products are used across diagnostic radiology, molecular imaging, radiation oncology, medical oncology, tumor board and elsewhere.

Mirada specializes in simplifying technically complex image processing tasks, allowing clinicians to more confidently diagnose disease, assess response to treatment and plan radiation therapy or surgical intervention.

Mirada's advanced software products are available throughout the world under its own brand, and on an OEM basis through a select number of the world's leading healthcare companies.

Mirada Medical was originally spun out of the University of Oxford. The company's technologies and products continue to be developed by their team of specialists, engineers and world-renowned scientists at Mirada's world headquarters in Oxford, England.

Mirada Medical, Mirada XD3, Caseaccess and Casemeeting are all trademarks of Mirada Medical Ltd.

For more information, visit www.mirada-medical.com.

About BioClinica, Inc.
BioClinica accelerates the development of new medical therapies by delivering expertise and technologies that enhance clinical research, worldwide. Our industry-leading medical imaging services, cardiac safety, and enterprise eClinical platform bring a new level of quality and efficiency to every phase of clinical development. Our experience spans three decades and includes thousands of studies in all therapeutic areas, from design and management, through submission and post-approval. BioClinica serves more than 400 pharmaceutical, biotechnology, and device companies – including all the top 20 - through a network of offices in the U.S., Europe, and Asia.